661 Dipeptidyl peptidase-9 (DPP9) overexpression is a potential response-predictive biomarker of BXCL701 and pembrolizumab combination treatment in mCRPC patients with SCNC phenotype

Схожие документы

• 1478 Dipeptidyl peptidase 4 (DPP4) inhibition is not solely responsible for the anti-tumor effects of BXCL701, an inhibitor of multiple DPPs, in a murine model of pancreatic ductal adenocarcinoma
  по: Vincent O’Neill, и др.
  Опубликовано: (2023-11-01)
• 341 Phase 1b/2 study of BXCL701, an oral activator of the systemic innate immunity pathway, combined with pembrolizumab (pembro), in men with metastatic castration-resistant prostate cancer (mCRPC)
  по: Lawrence Karsh, и др.
  Опубликовано: (2020-11-01)
• 382 Targeting innate immunity with BXCL701 in combination with pembrolizumab in patients with advanced solid cancers: phase 2 basket study
  по: Filip Janku, и др.
  Опубликовано: (2020-11-01)
• Management of elderly mCRPC patients
  по: Seiichiro Ozono
  Опубликовано: (2015-12-01)
• New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
  по: Chenkai Cui, и др.
  Опубликовано: (2022-09-01)